News | December 29, 2014

Societies Publish Data Standards for Cardiovascular Endpoints in Clinical Trials

Data establishes uniform data collection and common vocabulary

December 29, 2014 — The American College of Cardiology and the American Heart Association released clinical data standards for cardiovascular and endpoints in clinical trials.

The document, which was developed in collaboration with the U.S. Food and Drug Administration (FDA) and the Standardized Data Collection for Cardiovascular Trials Initiative, is the first step in developing a universal language to capture clinical event information across all types of clinical trials and other research and clinical evaluations. The data standards will facilitate the conduct of pooled analyses and meta-analyses to evaluate safety and effectiveness in clinical trials.  These data standards may also be used in clinical care processes, registries, electronic health records, longitudinal drug or device surveillance and other types of health-related research to capture key cardiovascular outcomes. This collaboration acknowledges the need to align clinical concepts for regulatory reporting and concepts for clinical care. 

For more information: www.cardiosource.org/ACC, www.heart.org

 


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now